Marburg Vaccine Shows Promising Results in First-In-Human Study

January 31, 2023 by TWN Staff
Marburg Vaccine Shows Promising Results in First-In-Human Study
Colorized scanning electron micrograph of Marburg virus particles (blue) both budding and attached to the surface of infected VERO E6 cells (orange). (NIH photo)

WASHINGTON — An experimental vaccine against Marburg virus, a member of the Ebola virus family that causes death in a large proportion of infected individuals, proved safe and induced an immune response in a small, first-in-human clinical trial.

The findings of the researchers at the National Institute of Allergy and Infectious Diseases were published in The Lancet.

According to their paper, the experimental MARV vaccine candidate, known as cAd3-Marburg, was developed at NIAID’s Vaccine Research Center using a modified chimpanzee adenovirus called cAd3, which can no longer replicate or infect cells.

The cAd3 vaccine platform demonstrated a good safety profile in prior clinical trials when used in investigational Ebola virus and Sudan virus vaccines developed by the VRC.

According to a press release on the National Institutes of Health website, many scientists believe MARV disease outbreaks in humans begin when the virus makes the jump from its primary animal host, which is likely to be certain chronically infected bats in sub-Saharan Africa. 

The symptoms of MARV disease are akin to those seen with Ebola virus disease and can include fever, headache, chills, rash, abdominal pain, vomiting and diarrhea. 

As the disease progresses, the release said, patients may suffer from multiple organ dysfunction, delirium and significant bleeding from the gastrointestinal tract or other sites that may result in death. 

No approved vaccines or specific therapies are available for MARV disease, aside from supportive care. 

While some experimental vaccines have previously been tested, none have proven to be both highly effective and to provide durable protection. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling outbreaks.

In this study, 40 healthy adult volunteers were enrolled at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland. 

They received a single dose of either a low dose of the vaccine (1×1010 particle units) or a higher dose (1×1011 particle units). For safety, the volunteers were enrolled in a dose-escalation plan. 

Three participants received the lower dose. Then, when they did not exhibit severe adverse reactions after the first seven days, the trial proceeded to enroll the remaining 17 volunteers. The same procedure was also used for the higher dose group. Volunteers were monitored for adverse reactions to the investigational vaccine and evaluated at regular intervals for 48 weeks to track their immune responses.

The trial’s safety results were encouraging: There were no serious adverse events and the experimental vaccine was well-tolerated. One participant in the higher dose group developed a fever following vaccination, but it resolved by the following day. 

In addition, the investigational vaccine appeared to induce strong, long-lasting immunity to the MARV glycoprotein: 95% of participants in the trial exhibited a robust antibody response after vaccination, and 70% maintained that response for more than 48 weeks.

Plans are in place to conduct further trials of the cAd3-Marburg vaccine in Ghana, Kenya, Uganda and the United States. If additional data supports the promising results seen in the phase 1 trial, the cAd3-Marburg virus vaccine could someday be used in emergency responses to MARV outbreaks, the institute’s release said.

Dan can be reached at [email protected] and @DanMcCue

A+
a-
  • Ebola virus
  • Marburg
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • In The News

    Health

    Voting

    Research

    March 13, 2024
    by Dan McCue
    Researchers Identify Brain Connections Associated with ADHD

    WASHINGTON — After examining more than 8,000 functional brain images of young people with ADHD, researchers have discovered their systems... Read More

    WASHINGTON — After examining more than 8,000 functional brain images of young people with ADHD, researchers have discovered their systems are tied to atypical interactions between the brain’s frontal cortex and the information processing centers deep inside the brain. The research into attention-deficit/hyperactivity disorder was conducted... Read More

    March 1, 2024
    by Dan McCue
    Solar Imports Surged in 2023, Tariff Waiver Set to Expire

    WASHINGTON — The United States saw an “unprecedented wave” of solar panels being imported from Southeast Asia last year, according... Read More

    WASHINGTON — The United States saw an “unprecedented wave” of solar panels being imported from Southeast Asia last year, according to a new analysis by S&P Global, the financial information and analytics firm.  Relying on data reported to the U.S. Census Bureau, S&P Global’s Market Intelligence... Read More

    February 14, 2024
    by Dan McCue
    COVID Vax, Booster During Pregnancy Bolsters Protections for Newborns

    WASHINGTON — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with significant protection... Read More

    WASHINGTON — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with significant protection against COVID-19 for at least six months after birth, a new study found. The research was conducted by the Infectious Diseases Clinical Research Consortium and published... Read More

    February 12, 2024
    by Dan McCue
    Scientists Set Record for Fusion-Generated Energy

    OXFORDSHIRE, U.K. — Researchers at a joint European testing facility set a record for the amount of energy generated from... Read More

    OXFORDSHIRE, U.K. — Researchers at a joint European testing facility set a record for the amount of energy generated from the process of nuclear fusion, but experts say machines capable of safely supplying that energy to the grid are still decades away. The breakthrough, announced on... Read More

    First US Lunar Lander in Over 50 Years Launched but Problem Develops on Way to Moon

    CAPE CANAVERAL, Fla. (AP) — The first U.S. lunar lander in more than 50 years rocketed to space Monday, launching... Read More

    CAPE CANAVERAL, Fla. (AP) — The first U.S. lunar lander in more than 50 years rocketed to space Monday, launching a race for private companies to deliver experiments and other items to the moon. But about seven hours after liftoff, Astrobotic Technology reported the solar panel... Read More

    December 20, 2023
    by Dan McCue
    Study Shows Parents’ Poor Health Literacy Inhibits Patient Care

    VIENNA, Austria — Poor health literacy on the part of a patient or caregiver may cloud their understanding of post-discharge... Read More

    VIENNA, Austria — Poor health literacy on the part of a patient or caregiver may cloud their understanding of post-discharge care instructions, threatening patient safety, a new study from the Medical University of Vienna found. The cross-sectional study conducted by Ph.D. student Fabian Eibensteiner and his... Read More

    News From The Well
    scroll top